T-lymphocyte-mediated immune response (CMI)

T-lymphocyte-mediated immune response, also known as cell-mediated immunity, is a complex adaptive immune process that relies on the activation of T-cells rather than antibodies to eliminate pathogens and abnormal cells (StatPearls, 2023). This response is triggered when T-cell receptors (TCRs) recognize specific antigens presented by major histocompatibility complex (MHC) molecules on the surface of other cells (Janeway's Immunobiology, 2017). It involves various T-cell subsets, including cytotoxic T-lymphocytes (CD8+) that directly kill infected or cancerous cells, and helper T-lymphocytes (CD4+) that coordinate the broader immune response through cytokine secretion (Nature Reviews Immunology, 2018). In clinical practice, this response is a major target for immunotherapy; checkpoint inhibitors are used to reactivate exhausted T-cells in cancer patients, while immunosuppressive drugs are employed to prevent T-cell-driven damage in autoimmune diseases and organ transplants (Journal of Clinical Investigation, 2015). The balance of this response is critical, as overactivity can lead to autoimmunity, while underactivity allows for the progression of infections and malignancies (Science, 2019).

Other names

Cell-mediated immunityT-cell mediated immunityCellular immune responseAdaptive cellular immunity

Drugs targeting this response function by either augmenting T-cell activity to treat cancer and infections or suppressing T-cell activation to manage autoimmunity and prevent transplant rejection (Nature Reviews Drug Discovery, 2020; StatPearls, 2023).